- Home
- NUV vs AZTA Comparison
NUV vs AZTA Comparison
Compare NUV & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUV
- AZTA
- Stock Information
- Founded
- NUV 1987
- AZTA 1978
- Country
- NUV United States
- AZTA United States
- Employees
- NUV N/A
- AZTA N/A
- Industry
- NUV Trusts Except Educational Religious and Charitable
- AZTA Industrial Machinery/Components
- Sector
- NUV Finance
- AZTA Technology
- Exchange
- NUV Nasdaq
- AZTA Nasdaq
- Market Cap
- NUV 1.8B
- AZTA 1.8B
- IPO Year
- NUV N/A
- AZTA 1995
- Fundamental
- Price
- NUV $8.53
- AZTA $29.64
- Analyst Decision
- NUV
- AZTA Buy
- Analyst Count
- NUV 0
- AZTA 3
- Target Price
- NUV N/A
- AZTA $50.67
- AVG Volume (30 Days)
- NUV 464.9K
- AZTA 703.4K
- Earning Date
- NUV 01-01-0001
- AZTA 08-05-2025
- Dividend Yield
- NUV 3.96%
- AZTA N/A
- EPS Growth
- NUV N/A
- AZTA N/A
- EPS
- NUV N/A
- AZTA N/A
- Revenue
- NUV N/A
- AZTA $669,171,000.00
- Revenue This Year
- NUV N/A
- AZTA N/A
- Revenue Next Year
- NUV N/A
- AZTA $4.89
- P/E Ratio
- NUV N/A
- AZTA N/A
- Revenue Growth
- NUV N/A
- AZTA 8.56
- 52 Week Low
- NUV $7.86
- AZTA $23.91
- 52 Week High
- NUV $9.08
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- NUV 45.95
- AZTA 54.22
- Support Level
- NUV $8.43
- AZTA $29.16
- Resistance Level
- NUV $8.62
- AZTA $30.86
- Average True Range (ATR)
- NUV 0.06
- AZTA 1.18
- MACD
- NUV 0.00
- AZTA 0.13
- Stochastic Oscillator
- NUV 50.00
- AZTA 70.88
About NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.